Shares of Kodiak Sciences Inc (NASDAQ:KOD) traded at a new 52-week high today of $170.90. This new high was reached on below average trading volume as 128,000 shares traded hands, while the average 30-day volume is approximately 273,000 shares.
Kodiak Sciences Inc is a clinical stage company. It is engaged in developing innovative therapeutics to treat high prevalence of ophthalmic diseases. The most advanced product candidate of the group is KSI-301, a biologic therapy built with antibody biopolymer conjugate platform, which is designed to maintain potent and effective drug levels in ocular tissue.
Kodiak Sciences Inc (NASDAQ:KOD) is currently priced 50.9% above its average consensus analyst price target of $80.75.
Over the past year, Kodiak Sciences Inc has traded in a range of $35.49 to $170.90 and is now at $164.32, 363% above that low.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer